What Is CJC-1295?
CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analogue designed to stimulate the body’s natural production of growth hormone (GH).
Unlike direct growth hormone administration, CJC-1295 works by signaling the pituitary gland to increase growth hormone release. Increased GH production may subsequently increase levels of insulin-like growth factor-1 (IGF-1), a hormone involved in recovery, tissue repair, metabolism, and body composition.
Two primary versions of CJC-1295 are commonly discussed:
- CJC-1295 DAC
- CJC-1295 No DAC
While both compounds act through the same receptor pathway, they differ significantly in duration of action and administration frequency.
CJC-1295 At A Glance
| Characteristic | CJC-1295 DAC | CJC-1295 No DAC |
|---|---|---|
| Category | GHRH Analog | GHRH Analog |
| Half-Life | Approximately 5–8 days | Approximately 30 minutes |
| Administration Frequency | 1–2 times weekly | 1–3 times daily |
| Growth Hormone Release | Sustained | Pulsatile |
| IGF-1 Elevation | Prolonged | Shorter Duration |
| Often Stacked With | Ipamorelin | Ipamorelin |
| Research Interest | Recovery, body composition, healthy aging | Recovery, sleep quality, body composition |
CJC-1295 DAC vs CJC-1295 No DAC
What Is DAC?
DAC stands for Drug Affinity Complex.
This modification allows CJC-1295 to bind to albumin in the bloodstream, dramatically extending its half-life. As a result, CJC-1295 DAC can remain active for approximately one week after administration.
The presence or absence of DAC is the primary difference between the two versions.
CJC-1295 DAC
CJC-1295 DAC was developed to provide prolonged stimulation of growth hormone release with less frequent administration.
Characteristics commonly discussed include:
- Weekly or twice-weekly administration
- Sustained growth hormone release
- Sustained increases in IGF-1
- Greater convenience
- Less resemblance to natural growth hormone pulses
Because GH and IGF-1 levels remain elevated for longer periods, researchers often investigate CJC-1295 DAC for long-term body composition and recovery applications.
CJC-1295 No DAC
CJC-1295 No DAC is a short-acting version designed to create a more natural pulsatile release of growth hormone.
This version is sometimes referred to as Modified GRF 1-29, although most users simply refer to it as CJC-1295 No DAC.
Characteristics commonly discussed include:
- Short half-life
- Multiple daily administrations
- Pulsatile growth hormone release
- Common pre-sleep administration
- Frequent pairing with Ipamorelin
Many researchers prefer this version because it more closely resembles natural growth hormone secretion patterns.
Which Version Is More Popular?
Both versions remain widely used in peptide research communities.
Researchers often choose CJC-1295 DAC when convenience and sustained IGF-1 elevation are priorities.
Researchers often choose CJC-1295 No DAC when the goal is to mimic natural growth hormone pulses and combine administration with compounds such as Ipamorelin.
Neither version is universally considered superior. The choice often depends on the specific goals of the research protocol.
How CJC-1295 Works
Growth Hormone Releasing Hormone Activity
CJC-1295 binds to GHRH receptors located within the pituitary gland.
Activation of these receptors signals the release of endogenous growth hormone, allowing the body to produce GH through its normal physiological pathways.
Increased IGF-1 Production
Growth hormone stimulates the production of IGF-1, primarily in the liver.
IGF-1 is commonly studied for its involvement in:
- Recovery processes
- Tissue repair
- Muscle growth
- Fat metabolism
- Cellular regeneration
Synergy With Ghrelin Pathways
CJC-1295 is frequently combined with Ipamorelin.
While CJC-1295 activates GHRH receptors, Ipamorelin stimulates ghrelin receptors. These pathways are believed to work together to amplify growth hormone release compared to either compound alone.
This combination remains one of the most commonly discussed peptide stacks for growth hormone support research.
Commonly Discussed CJC-1295 Protocols
CJC-1295 DAC Protocols
| Research Goal | Commonly Discussed Protocol |
|---|---|
| General Wellness Research | 1–2 mg weekly |
| Recovery Research | 1–2 mg weekly |
| Body Composition Research | 1–2 mg weekly |
| Long-Term Research | 1 mg every 3–7 days |
CJC-1295 No DAC Protocols
| Research Goal | Commonly Discussed Protocol |
|---|---|
| General Research | 100–200 mcg 1–3 times daily |
| Sleep Research | 100–300 mcg before sleep |
| Recovery Research | 100–200 mcg 2–3 times daily |
| Body Composition Research | Often paired with Ipamorelin |
Common CJC-1295 No DAC + Ipamorelin Protocol
| Compound | Commonly Discussed Amount |
|---|---|
| CJC-1295 No DAC | 100–300 mcg |
| Ipamorelin | 100–300 mcg |
| Frequency | 1–3 times daily |
This combination is among the most frequently discussed growth hormone secretagogue protocols within peptide research communities.
What Users Commonly Report
Weeks 1–4
Users commonly report:
- Improved sleep quality
- Deeper sleep
- Increased dreaming
- Better recovery between workouts
- Mild water retention
Weeks 4–8
Common reports include:
- Improved workout recovery
- Better training performance
- Enhanced body composition efforts
- Improved joint comfort
Weeks 8–16+
Longer-term reports frequently include:
- Gradual body composition improvements
- Enhanced recovery capacity
- Sustained sleep quality benefits
- Improved training consistency
Individual experiences vary considerably.
Potential Benefits
Researchers and users commonly discuss:
- Increased endogenous growth hormone production
- Increased IGF-1 levels
- Improved sleep quality
- Enhanced recovery
- Improved body composition
- Support for training performance
- Potential support for tissue repair
- Reduced recovery time between workouts
Research remains ongoing.
Potential Side Effects
Reported side effects may include:
- Water retention
- Temporary flushing
- Headache
- Injection site irritation
- Increased hunger
- Tingling sensations
- Fatigue
- Lightheadedness
Side effects appear to vary depending on protocol design, dosage, and individual response.
Frequently Asked Questions
Is CJC-1295 the same as growth hormone?
No. CJC-1295 stimulates the body’s natural production of growth hormone rather than supplying growth hormone directly.
Is CJC-1295 No DAC the same as CJC-1295 DAC?
No. Both compounds stimulate GHRH receptors, but CJC-1295 DAC contains a Drug Affinity Complex that dramatically extends its half-life.
Why do people stack CJC-1295 with Ipamorelin?
The compounds activate different receptor pathways and are believed to work synergistically to promote larger growth hormone pulses.
Which version lasts longer?
CJC-1295 DAC lasts significantly longer and may remain active for approximately one week after administration.
Which version is better for sleep research?
Many researchers prefer CJC-1295 No DAC because it produces shorter growth hormone pulses and is commonly administered before sleep.
Research Summary
CJC-1295 remains one of the most widely studied growth hormone secretagogues in peptide research.
Both CJC-1295 DAC and CJC-1295 No DAC stimulate growth hormone release through GHRH receptor activation, but they differ substantially in duration of action and administration frequency.
CJC-1295 DAC provides prolonged stimulation through its Drug Affinity Complex, allowing for less frequent administration. CJC-1295 No DAC produces shorter, more natural growth hormone pulses that often require multiple daily administrations.
As a result, both versions continue to attract research interest for recovery, body composition, sleep quality, healthy aging, and growth hormone physiology.
Related Guides
Continue your research with:
- Ipamorelin Protocols and Research Overview
- Sermorelin Protocols and Research Overview
- Tesamorelin Protocols and Research Overview
- BPC-157 Protocols and Research Overview
- MOTS-c Protocols and Research Overview
- Peptide Reconstitution Guide
- Peptide Stability and Storage Guide
- Peptide Testing and Quality Control Guide